Summary of Invention
Opioid receptors are G-protein coupled receptors, which mediate analgesic function, immune function, respiratory depression, constipation, nausea, sedation, and addiction. Most recent studies have shown that in addition to being localized to the brain, these receptors are also expressed in the peripheral nervous system, where they have been implicated in peripheral pain sensation and inflammation.
This invention centers on the discovery of two unique mammalian receptor systems, namely the Opioid (MOR-1) Receptors and the Orphanin/FQ (Nociceptin) Receptors. Multiple new receptors exist in both of these classes with discrete differences in binding profiles, in vivo expression, and function.
Advantages
- Useful targets in a high-throughput drug screen to identify both agonists and antagonists with an improved efficacy profile and minimal side effects.
- Novel receptors that can be used to discover new therapeutics for treatment of pain, constipation, addiction, and other indications.
- US and foreign patents pending cover multiple components of genes, proteins, antibodies, and drug discovery screening system.
Areas of Application
Targets for high-throughput drug screening.
Stage of Development
Animal studies completed.
Lead Inventor
Dr. Gavril Pasternak
Patent Information
- US patents either issued or under prosecution.
- US patents 6,627,734, 6,500,927, 5,747,279, and 6,660,496.
- Patent prosecution ongoing in Europe and in Canada.
References
Contact Information
Jeff Horenstein, PhD
Tel: 212-639-6181, Fax: 212-717-3439
E-mail: horenstj@mskcc.org
